Company Participants
Diane Weiser – Senior Vice President of Corporate Affairs
Robert I. Blum – CEO, President & Director
Andrew Callos – Executive VP & Chief Commercial Officer
Fady Malik – Executive Vice President of Research & Development
Stuart Kupfer – Senior VP & Chief Medical Officer
Sung Lee – EVP & CFO
Conference Call Participants
Huidong Wang
Salim Syed
Zaki Molvi – Jefferies LLC, Research Division
Carter Gould – Cantor Fitzgerald & Co., Research Division
James Condulis – Stifel, Nicolaus & Company, Incorporated, Research Division
Cory Kasimov – Evercore ISI Institutional Equities, Research Division
Caroline Poacher
Maxwell Skor – Morgan Stanley, Research Division
Yasmeen Rahimi – Piper Sandler & Co., Research Division
Roanna Clarissa Ruiz – Leerink Partners LLC, Research Division
Mayank Mamtani – B. Riley Securities, Inc., Research Division
Joseph Pantginis – H.C. Wainwright & Co, LLC, Research Division
Kyuwon Choi – Goldman Sachs Group, Inc., Research Division
John Gionco – Needham & Company, LLC, Research Division
Jason Zemansky – BofA Securities, Research Division
Presentation
Operator
Thank you for standing by, and welcome to the Cytokinetics Q3 2025 Earnings Conference Call. This call is being recorded and all participants will be in a listen-only mode. [Operator Instructions]
I would now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Affairs. Please go ahead.
Diane Weiser
Senior Vice President of Corporate Affairs
Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Andrew Callos, EVP and Chief Commercial Officer, will address commercial readiness activities for aficamten. Fady Malik, EVP of R&D, will provide updates related to the clinical development program and medical affairs activities for aficamten. Stuart Kupfer, SVP and Chief Medical Officer, will provide updates on the clinical development program for omecamtiv mecarbil and ulacamten. Sung Lee, EVP and Chief Financial Officer, will
Read the full article here